Related Experiment Video

Updated: May 20, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Progress of immune senescence in multiple myeloma treatment resistance

Yanan Jia1, Lixiang Yan1, Chenyang Fan1

  • 1Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, China.

Discover Oncology
|March 26, 2025
PubMed

Insights

Multiple myeloma (MM) drug resistance is a growing problem. Immune senescence, a decline in immune function, is linked to MM development and treatment resistance, suggesting new therapeutic targets.

Area of Science:

  • Hematologic Malignancies
  • Immunology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is a significant hematologic malignancy with increasing incidence.
  • Drug resistance remains a critical challenge in MM treatment.
  • Emerging evidence links the immune system, particularly immune senescence, to MM pathogenesis and treatment outcomes.

Purpose of the Study:

  • To review the relationship between immune senescence and multiple myeloma development.
  • To explore the role of immune senescence in MM drug resistance.
  • To identify potential immunotherapeutic targets for overcoming MM treatment resistance.

Main Methods:

  • Literature review of recent studies on immune senescence and multiple myeloma.
  • Analysis of the connection between immune system aging and MM progression.
  • Examination of immune senescence's impact on therapeutic responses in MM.

Main Results:

  • Immune senescence is increasingly recognized as a key factor in MM development.
  • Immune senescence plays a critical role in the emergence of drug resistance in MM.
  • Understanding immune senescence offers insights into therapeutic vulnerabilities.

Conclusions:

  • Immune senescence is implicated in both the development and drug resistance of multiple myeloma.
  • Targeting immune senescence may provide novel strategies to overcome treatment resistance in MM patients.
  • Further research into immune senescence mechanisms is crucial for advancing MM immunotherapy.
Keywords:
Drug resistanceImmunosenescenceMultiple myelomaTherapy

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
733